title: Statin use after acute myocardial infarction by patient complexity: are the rates right?
abstract: BACKGROUND
  Guidelines suggest statin use after acute myocardial infarction (AMI) should be close to universal in patients without safety concerns yet rates are much lower than recommended, decline with patient complexity, and display substantial geographic variation. Trial exclusions have resulted in little evidence to guide statin prescribing for complex patients.
  
  
  OBJECTIVE
  To assess the benefits and risks associated with higher rates of statin use after AMI by baseline patient complexity.
  
  
  METHODS
  Sample includes Medicare fee-for-service patients with AMIs in 2008-2009. Instrumental variable estimators using variation in local area prescribing patterns by statin intensity as instruments were used to assess the association of higher statin prescribing rates by statin intensity on 1-year survival, adverse events, and cost by patient complexity.
  
  
  RESULTS
  Providers seem to have individualized statin use across patients based on potential risks. Higher statin rates for noncomplex AMI patients were associated with increased survival rates with little added adverse event risk. Higher statin rates for complex AMI patients were associated with tradeoffs between higher survival rates and higher rates of adverse events.
  
  
  CONCLUSIONS
  Higher rates of statin use for noncomplex AMI patients are associated with outcome rate changes similar to existing evidence. For the complex patients in our study, who were least represented in existing trials, higher statin-use rates were associated with survival gains and higher adverse event risks not previously documented. Policy interventions promoting higher statin-use rates for complex patients may need to be reevaluated taking careful consideration of these tradeoffs.
authors.affiliation: *Arnold School of Public Health, University of South Carolina, Columbia, SC †Clinical Trials Statistical & Data Management Center, University of Iowa, Iowa City, IA ‡Arnold School of Public Health, University of South Carolina, Columbia, SC §Department of Pharmacy Practice and Science, University of Iowa ∥University of Iowa College of Public Health, Iowa City ¶Schneider Research Associates, LLC, Des Moines, IA #Health Economics Research Group, Brunel University London, Uxbridge, UK **University of Iowa College of Public Health, Iowa City, IA.
authors.forename: John M
authors.initials: JM
authors.lastname: Brooks
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Cook
authors.forename: Cole G
authors.initials: CG
authors.lastname: Chapman
authors.forename: Mary C
authors.initials: MC
authors.lastname: Schroeder
authors.forename: Elizabeth
authors.initials: E
authors.lastname: A Chrischilles
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Schneider
authors.forename: Puttarin
authors.initials: P
authors.lastname: Kulchaitanaroaj
authors.forename: Jennifer
authors.initials: J
authors.lastname: Robinson
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D007345:Insurance Claim Review / Q000706:statistics & numerical data; D008297:Male; D006278:Medicare / Q000706:statistics & numerical data; D009203:Myocardial Infarction / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D014481:United States
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors